MCID: OVR010
MIFTS: 33

Ovarian Brenner Tumor malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Brenner Tumor

Aliases & Descriptions for Ovarian Brenner Tumor:

Name: Ovarian Brenner Tumor 12 14
Brenner Tumor 42 69
Benign Ovarian Brenner Tumor 12
Benign Brenner Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2636
MeSH 42 D001948
NCIt 47 C3872 C39954
UMLS 69 C0006160

Summaries for Ovarian Brenner Tumor

Disease Ontology : 12 An ovarian benign neoplasm that has material basis in the surface epithelium of the ovary.

MalaCards based summary : Ovarian Brenner Tumor, also known as brenner tumor, is related to malignant ovarian brenner tumor and brenner tumor of ovary. An important gene associated with Ovarian Brenner Tumor is UPK3A (Uroplakin 3A). The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary and cervix, and related phenotype is renal/urinary system.

Related Diseases for Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 malignant ovarian brenner tumor 12.2
2 brenner tumor of ovary 11.0
3 cervix endometriosis 10.2 KRT20 UPK3A
4 neuroendocrine tumor 10.2 KRT20 UPK3A
5 vulva squamous cell carcinoma 10.2 KRT20 UPK3A
6 klatskin's tumor 10.2 KRT20 UPK3A
7 angiolipomatosis, familial 10.2 KRT20 UPK3A
8 myotonia congenita 10.2 KRT20 UPK3A
9 embryonal testis carcinoma 10.2 KRT20 UPK3A
10 secondary hyperparathyroidism of renal origin 10.1 KRT13 UPK3A
11 spinal cord oligodendroglioma 10.1 KRT13 KRT20
12 acute stress disorder 10.1 KRT20 WT1
13 papillary transitional carcinoma 10.1 KRT20 UPK3A
14 sphenoid sinus squamous cell carcinoma 10.1 KRT20 THBD
15 skin papilloma 10.1 KRT13 KRT20
16 avian influenza 10.1 THBD WT1
17 eccrine sweat gland neoplasm 10.1 THBD WT1
18 petrous apex meningioma 10.1 THBD WT1
19 neovascular glaucoma 10.1 KRT20 UPK3A
20 prostate stromal sarcoma 10.1 KRT20 THBD
21 wolffian duct adenoma 10.1 KRT20 THBD
22 persian gulf syndrome 10.0 THBD WT1
23 brown-vialetto-van laere syndrome 10.0 KRT20 WT1
24 dysembryoplastic neuroepithelial tumor 10.0 KRT20 UPK3A
25 renal pelvis carcinoma 10.0 PAX8 UPK3A
26 thymus gland disease 10.0 PAX8 UPK3A
27 spastic ataxia 5 10.0 KRT20 PAX8
28 exotropia 10.0 PAX8 WT1
29 diabetes persistent mullerian ducts 10.0 THBD WT1
30 clitoris cancer 10.0 KRT13 KRT20 UPK3A
31 rhinitis 10.0 KRT20 PAX8
32 transitional cell carcinoma 10.0
33 nodular tenosynovitis 9.9 PAX8 WT1
34 vulvar proximal-type epithelioid sarcoma 9.9 THBD WT1
35 extra-adrenal pheochromocytoma 9.9 PAX8 WT1
36 chondroblastoma 9.9 KRT20 THBD WT1
37 tumor of exocrine pancreas 9.9 KRT20 THBD WT1
38 myotonic disease 9.9 KRT20 THBD WT1
39 immunodeficiency 37 9.9 KRT20 THBD WT1
40 fuchs' heterochromic uveitis 9.8 PAX8 UPK3A WT1
41 thyroid carcinoma, papillary, with papillary renal neoplasia 9.8 PAX8 WT1
42 tenosynovitis of foot and ankle 9.8 KRT20 PAX8
43 meninges hemangiopericytoma 9.8 KRT20 PAX8 WT1
44 squamous cell carcinoma 9.8
45 endometrial stromal sarcoma 9.8
46 leiomyomatosis 9.8
47 sarcoma 9.8
48 uterine fibroid 9.8
49 cranial nerve disease 9.8 KRT20 PAX8 THBD
50 bernard-soulier syndrome, type c 9.5 KRT20 PAX8 WT1

Graphical network of the top 20 diseases related to Ovarian Brenner Tumor:



Diseases related to Ovarian Brenner Tumor

Symptoms & Phenotypes for Ovarian Brenner Tumor

MGI Mouse Phenotypes related to Ovarian Brenner Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 PAX8 THBD UPK3A WT1

Drugs & Therapeutics for Ovarian Brenner Tumor

Drugs for Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
5
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
8
Apixaban Approved Phase 3 503612-47-3 10182969
9
Dalteparin Approved Phase 3 9041-08-1
10
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
11
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
12
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
14
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
15 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 1,Phase 2
21 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
22 Micronutrients Phase 3
23 Trace Elements Phase 3
24 Antibodies Phase 3,Phase 1,Phase 2
25 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
26 Endothelial Growth Factors Phase 3,Phase 1
27 Immunoglobulin G Phase 3,Phase 1
28 Immunoglobulins Phase 3,Phase 1,Phase 2
29 Mitogens Phase 3,Phase 1
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Fibrinolytic Agents Phase 3,Early Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Early Phase 1
36 Analgesics Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 3,Phase 2
40 Carotenoids Phase 3
41 Anticoagulants Phase 3
42 Antithrombin III Phase 3
43 Antithrombins Phase 3
44 calcium heparin Phase 3
45 Factor Xa Inhibitors Phase 3
46 Heparin, Low-Molecular-Weight Phase 3
47 HIV Protease Inhibitors Phase 3
48
protease inhibitors Phase 3
49 Serine Proteinase Inhibitors Phase 3
50 Vitamin B Complex Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
6 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
7 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
8 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
9 Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Recruiting NCT03045406 Phase 3
10 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma Recruiting NCT02546102 Phase 3
11 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
12 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
13 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
14 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
15 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
16 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
17 Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer Unknown status NCT00845884 Phase 1, Phase 2
18 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
19 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
20 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
21 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
22 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2
23 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
24 Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00003076 Phase 2
25 Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Completed NCT01403610 Phase 2
26 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Completed NCT00056966 Phase 1, Phase 2
27 A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma Completed NCT01812603 Phase 1, Phase 2
28 A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients Completed NCT01812616 Phase 1, Phase 2
29 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
30 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
31 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
32 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma Recruiting NCT01906385 Phase 1, Phase 2
33 Low Dose Metronomic Poly-chemotherapy for Metastatic CRC Recruiting NCT02280694 Phase 2
34 TH-302 in Combination With Bevacizumab for Glioblastoma Recruiting NCT02342379 Phase 2
35 Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting NCT02205047 Phase 2
36 Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Recruiting NCT02614794 Phase 2
37 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression Recruiting NCT02858895 Phase 2
38 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2
39 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT01666444 Phase 2
40 TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma Not yet recruiting NCT03032484 Phase 2
41 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2
42 Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Terminated NCT00579137 Phase 1, Phase 2
43 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Unknown status NCT00408590 Phase 1
44 A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Unknown status NCT00559117 Phase 1
45 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1
46 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1
47 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1
48 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1
49 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1
50 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1

Search NIH Clinical Center for Ovarian Brenner Tumor

Cochrane evidence based reviews: brenner tumor

Genetic Tests for Ovarian Brenner Tumor

Anatomical Context for Ovarian Brenner Tumor

MalaCards organs/tissues related to Ovarian Brenner Tumor:

39
Ovary, Cervix

Publications for Ovarian Brenner Tumor

Articles related to Ovarian Brenner Tumor:

(show all 15)
id Title Authors Year
1
Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. ( 25596159 )
2015
2
Malignant ovarian Brenner tumor. A case report evaluated with (18)F-FDG PET/CT. ( 25890890 )
2015
3
FDG PET/CT of a benign ovarian Brenner tumor. ( 22920385 )
2012
4
A borderline ovarian Brenner tumor mimicks uterine fibroids. ( 21482385 )
2011
5
Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. ( 17581415 )
2007
6
Left ovarian Brenner tumor. ( 16302335 )
2005
7
Transitional cell carcinoma of the endometrium associated with a benign ovarian Brenner tumor: a case report. ( 11230712 )
2001
8
Leiomyomatosis peritonealis disseminata and ovarian Brenner tumor associated with tamoxifen use. ( 11520371 )
2001
9
Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. ( 10514386 )
1999
10
Doppler ultrasound in a patient with ovarian Brenner tumor of low malignant potential: comparison with Gray-scale ultrasound, magnetic resonance imaging and tumor marker suggesting malignancy. ( 9067723 )
1997
11
Squamous cell carcinoma of the cervix metastatic to an ovarian Brenner tumor. ( 7617659 )
1995
12
A case of ovarian Brenner tumor with stromal estrogenic activity. ( 8092962 )
1994
13
The histologic features and histogenesis of malignant ovarian Brenner tumor. ( 3100186 )
1986
14
The coexistence of an ovarian Brenner tumor and endometrial stromal sarcoma. ( 4542422 )
1973
15
The ovarian Brenner tumor; its gross and microscopic pathology. ( 14789894 )
1950

Variations for Ovarian Brenner Tumor

Expression for Ovarian Brenner Tumor

Search GEO for disease gene expression data for Ovarian Brenner Tumor.

Pathways for Ovarian Brenner Tumor

GO Terms for Ovarian Brenner Tumor

Biological processes related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.4 KRT13 KRT20
2 epithelial cell differentiation GO:0030855 9.37 UPK3A WT1
3 kidney development GO:0001822 9.33 PAX8 UPK3A WT1
4 branching involved in ureteric bud morphogenesis GO:0001658 9.32 PAX8 WT1
5 cellular response to gonadotropin stimulus GO:0071371 9.26 PAX8 WT1
6 metanephric S-shaped body morphogenesis GO:0072284 8.96 PAX8 WT1
7 metanephric epithelium development GO:0072207 8.62 PAX8 WT1

Sources for Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....